Solutions provider SMC Ltd has opened a new business offering pharmaceutical development services at the Cambridge Research Park in the UK.
Cambridge Pharma offers pharmaceutical development services, including sterile fill-finish and launches with a 20,000 sq. ft facility offering a range of manufacturing services for clinical trial development.
The sterile fill finish facility is designed to meet up-to-date regulatory requirements and includes independent HVAC systems and two clean rooms. Each clean room is equipped with isolators and fill finish equipment to support batch sizes from 100 units to 15,000 units in vials, cartridges, or syringes.
The company offers clients the option of taking a laboratory scale formulation and developing a process for clinical trials, including process development and filling of viscous formulations, suspensions, and gels.
Chetan N. Patel, Owner and CEO of SMC Group said: “We value pharmaceutical partnerships and continue to expand services in development, manufacturing and analytical testing to help accelerate drug product development. We are proud to launch ‘Cambridge Pharma’ as a part of our continued focus, growth and commitment to pharmaceutical products and services.”
Barbara Lead, Cambridge Pharma CEO said: “I am really proud of our new facilities and the experience and expertise of our teams. We can provide a range of pharmaceutical development services and we have experience with difficult to fill formulations. We aim to provide an excellent service to customers for clinical trial supplies which are always on the critical path to market.”
Tim Holden, Cambridge Pharma’s Commercial Director, added: “Our principal aim is to meet the challenging schedules Pharma clients face when planning clinical trial supplies. Our process development laboratory means we can support this, it certainly gives us an edge in completing timely technology transfer. We have the equipment and facilities designed specifically for smaller flexible manufacturing runs. Specialising in this service ensures that development timelines can be minimised, and cost savings can be made by our customers. We are very proud that our new facility has eco-friendly features which means we can help Pharma and Biotech companies meet their sustainability targets too.”